The price of Janssen’s esketamine for the treatment of treatment-resistant depression (TRD) exceeds commonly-cited $50,000-$150,000 quality-adjusted life year (QALY) cost thresholds, the Institute for Clinical and Economic Review (ICER) suggests in a recent evidence report.
ICER found esketamine treatments would cost around $198,000 per QALY.
The nasal spray treatment from Janssen, which was approved by the Food and Drug Administration in March, does display benefits for some patients, ICER found.
“Major depression is a severe and common condition, and new therapies are needed for the many people who are resistant to existing treatments,” ICER CMO David Rind said in a statement. “Esketamine shows some benefits for such patients and provides an FDA-approved treatment for TRD that may be covered by payers; however, it is concerning to have an overpriced therapy where there is such need for treatment.”
To read the full press release, click here.